ARTICLE | Company News

Duke spinout Grid gets IP for CFH antibodies

September 1, 2017 6:04 PM UTC

Duke University (Durham, N.C.) granted Grid Therapeutics LLC (Durham, N.C.), formerly Cue Biologics LLC, exclusive rights to IP covering antibodies that target complement factor H (factor H; CFH) to treat cancer, and CFH-related diagnostics. Duke received a stake in Grid as part of the deal.

In early 2019, Grid plans to start Phase I testing of lead candidate GT103, a recombinant IgG3 mAb targeting CFH, to treat advanced solid tumors...